If all you did was look at the headlines, you’d think this is a terrible time to invest in initial public offerings (IPOs).
Just take a look at this recent riff from Forbes, “Why WeWork Won’t Work! – Hello Neumann!,” or Bloomberg’s announcement, “Endeavor Makes Last-Minute Call to Yank IPO as Conditions Sour.” Big time financial news is clearly in love with the idea that anyone getting hyped up for a big name IPO is just setting themselves up for disappointment.
On paper, that narrative makes sense.
WeWork’s attempt at an IPO saw an optimistic estimated valuation of $47 billion falling to less than $14 billion before the offering was abandoned entirely. The loss was so devastating that the CEO resigned over it.
Not only that, but Peloton Interactive Inc. (PTON) dropped 11.2% in its first day of trading on Sept. 26, a decline which, according to The Wall Street Journal, directly influenced the decision of talent firm, The Endeavor Group, to also put off its own new stock debut out of fear of poor market conditions.
But what the media isn’t telling you is that tech and life sciences firms are still IPO leaders. That segment of the market is actually doing quite well overall.